Stock comparison
Halozyme Therapeutics
UnitedHealth
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
UNH
UnitedHealth
Market cap
$352.79B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | UNH | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 44D | HALO |
| Benjamin Graham | 83A | 67B | HALO |
| Philip Fisher | 65B | 29F | HALO |
| Peter Lynch | 53D | 23F | HALO |
| Joel Greenblatt | 40D | 37D | HALO |
| Charlie Munger | 80C | 36D | HALO |
| Terry Smith | 84A | 39D | HALO |
Side-by-side metrics
| Metric | HALO | UNH |
|---|---|---|
| Market cap | $8.1B | $352.79B |
| P/E (TTM) | 24.0x | 29.0x |
| EV/EBIT | 10.2x | 21.0x |
| ROIC (TTM) | 23.65% | 8.09% |
| Gross margin | 81.24% | 18.8% |
| Net margin | 23.13% | 2.68% |
| Revenue CAGR 5y | 33.23% | 11.69% |
| EPS CAGR 5y | -1.98% | -7.83% |
| Debt / Equity | 1.0x | 0.7x |
| Dividend yield | 0.0% | 2.3% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Net margin23.13%vs 2.68%+88%
- Gross margin81.24%vs 18.8%+77%
- EPS CAGR 5y-1.98%vs -7.83%+75%
- ROIC (TTM)23.65%vs 8.09%+66%
UNH leads on
- Dividend yield2.3%vs 0.0%+100%
- Market cap$352.79Bvs $8.1B+98%
- Debt / Equity0.7xvs 1.0x+21%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.